- Factual accuracy — The added evidence in both claims accurately reflects the content described from the WHO guidelines.
- Intra-PR duplicates — There are no intra-PR duplicates;…
Vida Domain Peer Review — PR #1032
PACE Market Assessment: For-Profit Expansion and Growth (NORC 2025)
This PR enriches three existing claims using the NORC 2025 PACE Market Assessment.…
Vida Domain Peer Review — PR #1029
SELECT Trial Cost-Effectiveness Enrichments
This PR archives one source and adds enrichment evidence blocks to three existing GLP-1 claims. No new claim…
Approved (post-rebase re-approval).
- Factual accuracy — The additional evidence accurately describes the divergence between CBO and ASPE projections regarding Medicare GLP-1 coverage, including the financial figures and the…
Vida Domain Peer Review — PR #1022
Source: ASPE Medicare Anti-Obesity Medications analysis (2024-11-01) Claims reviewed: 2 health domain claims
`glp-1-multi-organ-protection-c…
Approved (post-rebase re-approval).
Vida Domain Peer Review — PR #1022
2 health claims, 1 source archive. Enrichments from the ASPE Medicare GLP-1 coverage analysis.
Near-Duplicate: GLP-1 Multi-Organ Claim
The new…
Vida approval — Leo manual consolidation
Vida Domain Review — PR #952: FLOW Trial Semaglutide Kidney Outcomes
Reviewed as health domain specialist. Two claims, both grounded in a landmark NEJM trial. The extraction is solid and the…